Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
| ▸ | CES2 | O00748 | 5/20 | 0.46 |
| ▸ | CES1 | P23141 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23112580 | 0.89 | KDM4E (0.47) | ACHECES2CES1KDM4EMEN1 | |
| SCHEMBL9567088 | 0.86 | MEN1 (0.51) | KDM4EMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL10322782 | 0.81 | KMT2A (0.47) | KDM4EMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL20787058 | 0.81 | KDM4E (0.42) | ACHECES2CES1KDM4EMEN1 | |
| SCHEMBL5077504 | 0.81 | CES1 (0.43) | CES1KDM4EMEN1KMT2ANPSR1 | |
| SCHEMBL6061145 | 0.80 | KDM4E (0.38) | ACHECES2CES1KDM4EMEN1 | |
| SCHEMBL6061485 | 0.80 | KDM4E (0.41) | ACHECES2CES1KDM4EMEN1 | |
| SCHEMBL23112434 | 0.79 | POLB (0.43) | KDM4EMEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL2891142 | 0.78 | KDM4E (0.47) | ACHECES2CES1KDM4EMEN1 | |
| SCHEMBL5578230 | 0.78 | SMN1; SMN2 (0.45) | MEN1KMT2ASMN1; SMN2NPSR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106077-B2 | Compounds and methods for modulating FXR | ELI LILLY AND COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| EP-2029558-B1 | COMPOUNDS AND METHODS FOR MODULATING FXR | LILLY CO ELI (US) | 2010-03-10 | — | — | EP | disclosed |
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-04-09 | — | — | US | disclosed |
| EP-2029558-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2009-03-04 | — | — | EP | disclosed |
| US-7378474-B2 | Olefin polymerization catalyst | KANEKA CORPORATION (JP) | 2008-05-27 | — | — | US | disclosed |
| US-7378474-B2 | Olefin polymerization catalyst | KANEKA CORPORATION (JP) | 2008-05-27 | — | — | US | disclosed |
| WO-2007140174-A2 | COMPOUNDS AND METHODS FOR MODULATING FXR | ELI LILLY AND COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| US-20070244261-A1 | Polyolefin Graft Copolymer, Composition and Method for Producing Same | KANEKA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070244261-A1 | Polyolefin Graft Copolymer, Composition and Method for Producing Same | KANEKA CORPORATION (JP) | 2007-10-18 | — | — | US | disclosed |
| US-20070167316-A1 | Olefin polymerization catalyst | KANEKA CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20070167316-A1 | Olefin polymerization catalyst | KANEKA CORPORATION | 2007-07-19 | — | — | US | disclosed |
| EP-1762579-A1 | POLYOLEFIN GRAFT COPOLYMER, COMPOSITION AND METHOD FOR PRODUCING SAME | Kaneka Corporation (JP) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093524-A1 | COMPOUNDS AND METHODS FOR MODULATING FXR | NR1H4, SLC10A1, FXR1 | ACHE 4221/4885CES2 370/4885CES1 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.